DRUG TARGET REVIEW: In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted Amphiphile-Immunotherapy to enhance anti-tumour function and eradicate solid tumours.

BIOSPACE: Finally, Elicio Therapeutics is expected to present the first-ever data from the 7P formulation of its off-the-shelf cancer vaccine candidate, ELI-002 7P, targeting KRAS/NRAS-mutated solid tumors. The interim data will come from the Phase Ia safety arm of the AMPLIFY-7P trial that was initiated in April 2023.